The initial success of the copyright undeniably reshaped the drug landscape, but placing funds in companies strongly reliant on off-patent versions presents a complex picture. Despite early earnings were substantial, the end of patents and the rise of less expensive alternatives have diminished market share. Consequently, a thorough evaluation of p